Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer
Verified date | January 2014 |
Source | Atlantic Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. Transimmunization is a treatment of the blood designed to boost the immune response against lung cancer. Transimmunization uses a device called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day.
Status | Terminated |
Enrollment | 16 |
Est. completion date | April 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed non-small cell lung cancer Stage IIIB. Previously treated with two prior chemotherapy regimens or refused chemotherapy, and able to receive definitive RT. (Patients will not receive chemotherapy during the study). Patients with malignant pleural effusion are not eligible. - Stage IV with measurable disease in the lung and a medical indication for radiation therapy. (Patients will not receive chemotherapy during the study). These patients must have received and progressed on two prior chemotherapy regimens or have refused chemotherapy. - Staging by CT scan of chest/abdomen and MRI of brain. - Willing and able to undergo two (baseline and follow-up) bronchoscopy with BAL and bronchial biopsy for bronchoscopically visible tumor. - No treatment for lung cancer (chemotherapy, radiation therapy, biomodifiers) for 4 weeks prior to entry. - Stable or progressive disease. - No concurrent infection. - Able to tolerate fluid shifts related to photopheresis (removal of 250 cc of blood and subsequent reinfusion of 250 cc of blood over 1-2 hours). - ECOG Performance Status < 2. - At least 18 years of age. - Adequate bone marrow reserve: hemoglobin > 11 g/dL; platelet count > 100,000 mm3; ANC > 1500/ mL. - Life expectancy of greater than 3 months. - Normal peripheral CD8 count. - Not pregnant or nursing. - PFTs demonstrating diffusion capacity = 60%, FEV1 = 60%, and vital capacity = 60%. - Radiotherapy would be offered as appropriate standard therapy outside of a study setting. Exclusion Criteria: - History of or active infection with human immunodeficiency virus (HIV), hepatitis B (by antigenemia), or hepatitis C. - History of allergic reactions attributed to compounds of similar composition to 8-methoxypsoralen (oxsoralen, trisoralen). - Significant cardiovascular disease (i.e. NYHA class 3 or higher congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias) - Pregnant or nursing at time of study entry. - Participation in an investigational drug trial within 30 days prior to screening. - Suspected or confirmed poor compliance, mental instability, or prior or current alcohol or drug abuse deemed by the Investigator to be likely to affect their ability to sign the informed consent, or undergo study procedures. - Presentation with, or a recent history (within 24 hours) of a fever = 38.2°C or symptoms of significant local infection or systemic infection, including urinary tract infections - such patients will be deferred from enrollment at least until 48 hours after illness has resolved. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Morristown Memorial Hospital | Morristown | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Atlantic Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The purpose of this study is to determine the safety of using a treatment called transimmunization in addition to standard therapy (radiation) in the treatment of lung cancer. | 1-2 yrs | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |